new antiviral of plant origin
Active substance
Panavir is a phytogenic biologically active polysaccharide with molecular weight of 2 megadalton relating to the group of hexose glycoside.
Monosaccharides composition (%):
Xylose - 1.5;
Rhamnose - 9.0;
Glucose - 38.5;
Galactose - 14.5;
Mannose - 2.5;
Uronic acids - 3.5.
DOSAGE FORM
Isotonic liquid based solution for infusion is produced in ampoules by 5,0 ml., 2ml.,1 ml in concentration of 0.004%, 0.01% and 0.02% accordingly (0.2 mg active substance).
MECHANISM OF ACTION
· Panavir is a protector and it defends body's cells from viruses attacks.
· The drug is able to inhibit viruses' replication in infected cell cultures and causes significant reduction of titres of infectious virus' activity.
· The drug Panavir enhances viability of infected cells.
Pharmacokinetics
After administering Panavir intravenously, polysaccharides are discovered in blood in 5 minutes after injection made and are captured by the cells of reticuloendothelial system of liver and spleen. It is washed out through kidneys, after 20-30 minutes passed polysaccharides are revealed in urine.
The trials have shown absence of:
Mutagenic,
Teratogenic,
Cancerogenic,
Allergenic,
Embryotoxic action
PRESCRIPTION TO APPLICATION
The antiviral Panavir is assigned for treatment of infection contamination caused by DNA and RNA viruses. Chronic recurrent herpes infections (HSV 1, 2, H.Zoster, CMV)
Human papillomavirus infection (HPV)
Viral dermatosis
Mite-borne encephalitis
The ways of application
Herpes: 5 ml intravenously (I/V) twice; dosage interval - 48 hours; reiterate the course of treatment in a month or in exacerbation period.
Papilloma virus infection: 5 ml I/V 5 times; dosage interval: the first 2 injections - 48 hours, the subsequent - one time a week.
Mite-borne encephalitis: 5 ml I/V 3 times; dosage interval - 48 hours.
Administer solution Panavir intravenously slowly by squirts.
Side effects
The medication is tolerated well; possible complications might be caused by individual intolerance to the drug or heightened sensibility to the constituents of the medication.
The report on clinical study of Panavir efficiency carried out in the Central Scientific Research Institute of Dermatology and Venereology of the Health Ministry of the Russian Federation.
Table 1
ESTIMATION OF THE TREATMENT EFFICIENCY |
Number of patients
Recurrence duration |
Before treatment |
After treatment |
17 |
less than 7 days |
5.1 days |
31 |
7-10 days |
5.9 days |
12 |
11 days and more |
6.8 days |
Total: 60 |
|
5.9 days | | |
